RecruitingNot ApplicableNCT07557225

18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors

Evaluation of Diagnostic Value of 18F-T2 PET/ CT Imaging for Tumors Likely to Express High Levels of CAIX

Sponsor

Peking University First Hospital

Enrollment

200 participants

Start Date

Apr 27, 2026

Study Type

INTERVENTIONAL

Conditions

Breast Cancer Colorectal, Cancer Pancreatic Cancer Ovarian Cancer Cervical Cancer Endometrial Cancer Cholangiocarcinoma Head and Neck Cancer Non-small Cell Lung Cancer Hepatocellular Carcinoma (HCC)Small Cell Lung Cancer Clear Cell Renal Cell Cancer (ccRCC)Urothelial Carcinoma (UC)Von Hippel-Lindau Disease

Summary

The goal of this clinical trial is to evaluate the diagnostic value of CAIX protein specific probe 18F-T2 in PET/CT imaging in participants with solid tumors. It will also assess the safety, tolerability and radiation dosimetry of 18F-T2.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying 18F-T2 PET/CT for people with breast cancer, cervical cancer, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TEST18F-T2 PET/CT

18F-T2 is injected intravenously with a dose of 0.05-0.10 mCi/kg. The CT and PET imaging session will begin approximately 60 minutes after 18F-T2 administration.

Locations(1)

Peking University First Hospital

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07557225

Related Trials

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

NCT066944541 location

Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors

NCT021461701 location